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Abstract
Background: Cervical cancer is the fourth most common cancer among women worldwide, many of who are still
within their reproductive lifespan. Advances in screening and treatment have increased the 5-year survival for early
stage disease to over 90 % in developed countries. The focus is now shifting to reducing morbidity and improving
fertility outcomes for cervical cancer patients. Radical trachelectomy with lymph node assessment became the
standard of care for selected women with lesions <2 cm who desire fertility preservation. However, several
questions still remain regarding the degree of surgical radicality required for tumors <2 cm, and fertility-sparing
options for women with early-stage disesase ≥2 cm, and those with more advanced disease. Here, we compile a
narrative review of the evidence for oncologic and pregnancy outcomes following radical trachelectomy, non-
radical fertility-sparing surgery, and the use of neoadjuvant chemotherapy prior to surgery for larger lesions. We
also review the literature for assisted reproductive technologies in women with more advanced disease.
Findings: Available literature suggests that the crude recurrence and mortality rates after radical trachelectomy are
<5 and <2 %, respectively (approx. 11 and 4 % for tumors ≥ 2 cm). Among 1238 patients who underwent fertility-
sparing surgery for early cervical cancer there were 469 pregnancies with a 67 % live birth rate. Among 134 cases
with lesions ≥ 2 cm, there were ten conceptions with a live birth rate of 70 %. Outcomes after non-radical surgery
(simple trachelectomy or cervical conization) are similar, although only applicable among a highly selected patient
population. For patients ineligible for fertility-preserving surgery or who require adjuvant radiation therapy, current
options include ovarian transposition and cryopreservation of oocytes or embryos but other techniques are under
investigation.
Conclusion: Today, many cervical cancer survivors have successful pregnancies. For those with early-stage disease,
minimally invasive and fertility sparing techniques have resulted in improved obstetrical outcomes without
compromising oncologic safety. Results from three ongoing trials on non-radical surgery for low-risk tumors <2 cm
will further inform the need for radical surgery in such patients. For those in whom natural childbearing is
unachievable, advances in assisted reproductive technologies provide reproductive options. Despite our advances,
the effects of cervical cancer survivorship on quality of life are not fully elucidated.
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Background
Cervical cancer is the fourth most common cancer in
women worldwide, with over half a million new cases
diagnosed annually [1]. It affects women at a significantly
younger age than most other malignancies. According to
the Surveillance, Epidemiology, and End Results (SEER)
database, between 2008 and 2012, 39 % of new cases diag-
nosed in the US were in women under the age of 45 [2].
Over the past several decades, most developed countries
have seen a significant reduction in overall mortality with
5-year survival rates for localized disease surpassing 90 %
[2]. Combined with a trend towards delayed childbearing,
this has resulted in a cohort of cervical cancer survivors
who are still well within their reproductive lifespan.
Loss of fertility, regardless of cause, is a source of
significant psychological distress among women [3].
Several studies suggest that cervical cancer survivors
have significantly more reproductive concerns, com-
pared to age-matched controls, including grief about
inability to bear children, and an inability to talk openly
about fertility [3, 4]. In 2006 the American Society of
Clinical Oncology highlighted the importance of ad-
dressing future fertility and potential fertility preserva-
tion options with patients prior to cancer therapy [5].
Radical trachelectomy (RT) was first described by
Eugen Aburel for the treatment of early-stage cervical
cancers in the 1950s [6]. This technique was all but
forgotten until the 1990s when it was revitalized by
Dargent et al. in 1994 [7], to preserve fertility in selected
cases through a vaginal approach (VRT). This ushered in
a new era of fertility-sparing options for women with
early-stage cervical cancer. Over two decades of accu-
mulated data show that for women with small volume
disease, this procedure has acceptable surgical morbidity
and oncological outcomes [8]. As a result, radical trache-
lectomy, with pelvic lymph node assessment, became the
standard of care for selected women early-stage with
disease <2 cm who desire to maintain their fertility [9].
However, several questions still remain about the
degree of radicality required, as well as the optimal
management of lesions greater than 2 cm. There
continues to be a push towards less invasive procedures
to reduce peri-operative morbidity, and reduce preterm
delivery and perinatal morbidity without compromising
oncologic safety. The purpose of this review is to
examine the current state of fertility sparing manage-
ment of cervical cancer, including management of ≥2 cm
early stage disease and novel technologies in assisted
reproduction for women with locally advanced disease.
Main text
Methods
We searched Ovid EMBASE (from 1974 to 2016 week
13) and Ovid MEDLINE in process & other non-indexed
citations (from inception to March 2016) for relevant
citations. We performed key-word searches combining
various disease-specific terms (e.g. cervical cancer,
uterine cervix carcinoma) with treatment specific terms
(e.g. trachelectomy, conization, neoadjuvant chemother-
apy). We limited our search to English language studies.
To identify ongoing planned or unpublished trials, we
searched the US National Institute of Health’s clinical
trial registry at ClinicalTrials.gov. All searches were
supplemented by hand searching the reference lists of
key papers for relevant citations. Articles were organized
based on topics deemed to be relevant by the authors.
Crude recurrence, mortality, and birth rates were calcu-
lated from large reports of radical trachelectomy overall,
radical trachelectomy for lesions ≥2 cm, non-radical
fertility sparing procedures, and fertility-sparing proce-
dures after neoadjuvant chemotherapy. Where follow-up
studies were available, we included only the most recent
and complete series to avoid double counting patients. A
narrative review of these topics is presented here.
Early-stage disease
Early-stage cervical cancer includes disease that is
confined to the cervix, measuring ≤ 4 cm, with no appar-
ent spread to adjacent structures or distant organs
(International Federation of Gynecology and Obstetrics-
FIGO- stages IA1-IB1) [10]. Given the low risk (≤1 %) of
either pelvic lymph node or parametrial involvement in
stage 1A1 squamous cell carcinoma of the cervix,
standard treatment usually consists of cone biopsy or
extrafascial hysterectomy, depending on the patient’s
desire for fertility preservation [10, 11]. Traditional
thinking has dictated that beyond stage IA1 (or in the
presence of other high risk features) the increased risk
of local spread to the parametria and upper vagina
necessitates a more radical surgical approach including
lymph node assessment.
Excellent oncological outcomes have been obtained with
radical hysterectomy accompanied by bilateral pelvic
lymph node dissection for early-stage disease. Five-year
overall survival rates range from 73 to 98 % [12–14].
However, this procedure carries a significant risk of surgi-
cal morbidity, including increased blood loss, transfusion,
and injuries to the bladder, bowel, ureters, and obturator
nerve [15–17]. Long-term bladder, anorectal, and sexual
dysfunction have been described [18–20]. Over time,
minimally invasive and nerve sparing approaches have
been developed to reduce morbidity [10], and the degree
of surgical radicality required has been challenged with
favourable survival and recurrence rates [21, 22].
Eligibility for fertility sparing management
To be eligible for fertility sparing management of
cervical cancer, two main criteria must be met; 1) the
Willows et al. Gynecologic Oncology Research and Practice  (2016) 3:9 Page 2 of 14
patient’s desire for, and likelihood of, fertility must be
sufficiently high, and 2) oncologic safety must be accept-
able. A pre-operative fertility workup may be considered,
particularly in those with a history of infertility [23]. The
patient’s age should be considered with respect to
ovarian reserve and the increased risk of pregnancy
complications with advanced maternal age [23, 24].
Eligibility for fertility-sparing surgery should reflect local
jurisdicational age-related eligibility policies for assisted
reproductive technologies.
Oncologic safety can be assessed in terms of clinico-
pathologic risk factors for recurrence. These include
tumour size, depth of stromal invasion, presence of
lymphovascular space invasion (LVSI), lymph node and
parametrial involvement and the feasibility of achieving
tumour-free margins [25–27].
Clinical stage, including vaginal and parametrial
spread, should be assessed by an expert (e.g. Gyneco-
logic Oncologist) [23]. Although tumours > 2 cm are at
greater risk of lymph node metastasis and recurrence
[28, 29], there is a general consensus that larger, expohy-
tic tumours with minimal stromal invasion may be
considered for fertility-sparing procedures [30, 31]. In a
small prospective trial of 30 patients desiring fertility-
preservation, magnetic resonance imaging was shown to
have 100 % positive and negative predictive value in
assessing suitability for radical trachelectomy [32].
For early stage disease, the difference in recurrence
and mortality between squamous carcinomas and adeno-
carcinomas seems negligible, and both may be consid-
ered as candidates for fertility-preservation [33, 34]. A
review at our centre found no significant difference in
recurrence free survival between 74 patients with adeno-
carcinoma and 66 patients with squamous cell carcin-
oma treated with radical vaginal trachelectomy [35].
Although there have been reports of higher incidence of
ovarian involvement in adenocarcinoma of the cervix,
compared to squamous carcinomas, the overall risk
remains low. A review by Touhami and Plante reported
a 2 % incidence of ovarian metastasis among those with
stage 1B adenocarcinomas of the cervix, among which
96.7 % had other clinical and pathologic features that
would preclude fertility-sparing [36]. The authors argue
that the risk of surgical menopause in the pre-
menopausal population eligible for fertility-sparing
outweighs the risk of ovarian involvement, and therefore
advocate that ovarian preservation remains an option in
the case of early adenocarcinomas of the cervix.
However, non-squamous, non-adenocarcinomas have
significantly worse prognosis [37]. In a few early series
that included neuroendocrine carcinomas for fertility-
sparing, rapid recurrence was observed [28–30]. Many
have thus questioned the inclusion of these aggressive
histologies in fertility sparing procedures. LVSI alone
should not preclude fertility-sparing management. A
review by Beiner et al. found that among patients under-
going radical vaginal trachelectomy, 28 % had LVSI, and
only 5 % had nodal metastases [38]. While exclusion on
this basis is unmerited, extensive LVSI does put these
patients at increased risk of nodal involvement [39].
Little prospective data exists as to the optimal surgical
margin for trachelectomy specimen. A retrospective
review by McCann et al. found that for patients with
stage 1A2–2A cervical cancer undergoing radical hyster-
ectomy, close surgical margins (defined as margins
≤5 mm), while not an independent risk factor for
recurrence, were associated with other intermediate and
high risk features, including lymph node positivity,
parametrial involvement, increased size of primary le-
sion, increased depth of stromal invasion and LVSI [40].
Coincidently, most experts in the area had previously
empirically adopted 5 mm as the minimum margin
[41, 42]. Therefore, based on extrapolation of data on
recurrence following radical hysterectomy and the above
empiricism, we believe that optimal surgical margins after
fertility-sparing management are at least 5 mm.
Lymph node assessment
Assessment for lymph node metastases is critical for any
patient with greater than 3 mm depth of invasion (i.e. >
stage IA1) or other high risk features (e.g. LVSI, high-
risk histologies) on a biopsy specimen. Suspicious nodes
should be sought on pre-operative CT or MRI but the
sensitivity and specificity of these modalities in early
cervical cancer is modest, given the low prevalence of
enlarged nodes in this population [11]. Combined
PET-CT may identify small metastases, however the
utility and significance of these remains controversial,
particularly in those receiving neoadjuvant chemother-
apy prior to surgical management [43].
In the absence of grossly positive nodes on imaging,
definitive nodal assessment must be made operatively.
Frozen section may be utilized to assess for nodal
metastases and positive surgical margins, in which case
fertility-sparing surgery may be aborted, or the surgical
procedure altered (eg. complete ipsilateral pelvic and
para-aortic lymphadenectomy). However, frozen section
is not universally practiced due to the concerns regard-
ing false negatives, and loss of tissue for permanent
pathological processing. A range of false negative rates
for intra-operative frozen section in early cervical cancer
has been reported. For stage 1A2–1B1, Panici et al.
report a false negative rate of 4.2 % [44]; for stage
1B1–2B, Scholz et al. report a false negative rate of 19 %
[45]. Since 2015, the National Comprehensive Cancer
Network (NCCN) recommends the consideration of
sentinel lymph node procedure (SLNP) for early-stage
cervical cancer measuring less than 2 cm [9]. Gortzak
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examined the use of sentinel lymph node procedure
among 81 women undergoing successful sentinel lymph
node procedure for early cervical cancer (stage 1A–1B1).
They reported a false negative rate of 21.4 % (3/14
negative sentinel nodes). Two of the three cases involved
micrometastases <2 mm found only after ultrastaging,
highlighting the importance of this element of the
sentinel lymph node procedure [46]. Despite a high false
negative rate, intraoperative frozen section remains
useful in this setting, due to the low prevalence of nodal
involvement in early cervical cancer. In this case, the
finding of a negative node on frozen section has a
negative predictive value of over 97 % [47, 48].
It is recommended that both intraoperative, and final
pathology be reviewed by a pathologist specializing in
gynecology and that ultrastaging be performed for senti-
nel lymph nodes. Ultimately, the clinician needs to
evaluate all available information, and come to a
decision regarding further surgery to define the extent of
disease (staging), versus adjuvant therapy be it chemo,
radiation, or both- the former not necessarily precluding
fertility sparing.
Radical fertility-sparing surgical management
Radical vaginal trachelectomy (VRT) accompanied by
laparoscopic pelvic lymph node dissection has become
an accepted treatment modality for fertility preservation
in early cervical cancer measuring <2 cm. In 2007, a
review of 520 cases found a recurrence and mortality
rate of 4.2 and 2.8 %, respectively [49].
Radical trachelectomy can also be performed abdom-
inally (ART), laparoscopically (LRT), and robotically
(RRT). An advantage to these alternative approaches is
that they more closely resemble the radical hysterectomy
familiar to gynecologic oncologists, and do not require
special skills in vaginal surgery [34]. Additionally, an
abdominal approach allows for potentially greater para-
metrial resection compared to the vaginal approach [50].
In 2013, Cao et al. performed a matched case-control
study comparing surgical approaches in 126 patients
undergoing radical trachelectomy [51]. They found no
significant differences between VRT and ART for mean
operating time, perioperative complications or postoper-
ative complications. Although VRT resulted in higher
pregnancy rates (35.5 v. 8.8 %) and live birth rates (23.3
v. 8.8 %), it also resulted in higher rates of recurrence
(9.8 v. 0 %) and death from disease (2.8 v. 0 %) [51]. Our
review of large case series’ of radical trachelectomy
identified oncologic outcomes in 1312 patients eligible
for fertility sparing management of early cervical cancer
(Table 1). After accounting for adjuvant treatments,
91 % successfully preserved their fertility. The crude
recurrence and mortality rates in this group were 4.5
and 1.7 %, respectively. We identified 13 studies that
reported individual-level data on recurrences after rad-
ical trachelectomy. Fifty-six patients recurred at a me-
dian of 18 months after surgery (range 3–108 months).
The majority (66 %) of recurrent cases had evidence of
intermediate or high-risk features on surgical pathology, or
a non-squamous, non-adenocarcinoma histology (Table 2).
Once tumour-free margins (>5 mm) have been
achieved, many surgeons insert a cerclage suture around
the lower uterine segment, in anticipation of future
pregnancy [34]. In an attempt to prevent isthmic
stenosis (which occurs in approximately 15 % of cases
[52]) we suture a rubber catheter into the os of the lower
uterine segment. In our center, this is removed 3 weeks
post-operatively [34]. Alternatively, some advocate for
the routine use of a temporary intrauterine device for
this purpose [53]. If stenosis is suspected, cervical dilata-
tion can be performed [52]. Our review of obstetrical
outcomes among 1238 patients who had undergone
successful fertility-sparing management for early cervical
cancer identified 469 pregnancies, resulting in a 67 %
crude live birth rate (Table 3).
Regardless of the approach, higher recurrence rates
have been found in patients with larger tumours [51].
Our review of the literature identified 189 cases (for
which individual-level data was extractable) of lesions
>2 cm eligible for radical trachelectomy (Table 4).
Among those who successfully underwent fertility spar-
ing surgery, we identified an overall crude recurrence
rate of 11 % and a crude disease-related mortality rate of
4 %. Many feel that lesions ≥2 cm should be triaged to
the abdominal approach, where a wider parametrial
resection is more attainable [50, 54]. The use of neoadju-
vant chemotherapy in this population is discussed below.
Furthermore, we identified 134 cases of lesions ≥2 cm
where fertility sparing management was successful,
resulting in ten conceptions, with a live birth rate of
70 % (Table 5). Ultimately, approximately 25–30 % of
women who try to conceive post radical trachelectomy
will be infertile [52]. Although three quarters of cases
can be attributed to cervical factor, the remaining cases
are due to other causes, highlighting the importance of a
pre-operative fertility workup in some cases [52].
Non-radical surgical management
Parametrectomy is responsible for the majority of
complications related to radical surgery [55]. Among a
subgroup of patients with low-risk pathologic features
(lesion <2 cm, depth of invasion <10 mm, and negative
pelvic nodes), the risk of paramentrial involvement is
estimated to be as low as 0.6 % (90 % CI 0–1.1 %) [56].
Furthermore, after diagnostic LEEP/conization proce-
dures, approximately 65 % of radical trachelectomy
specimens have no residual disease [57–59]. Therefore,
many patients with early cancers are over-treated at the
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Table 1 Oncologic outcomes after radical trachelectomy (where N > 100 reported)
Study Eligible for
fertility sparing (N)
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93)
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2 9 83 0 0 51 (10–147)
Total N = 1312 N = 1190 N = 53 N = 20




Abbreviations: LVSI+ presence of lymphovascular space invasion, LN+ lymph node metastasis, SCC squamous cell carcinoma, AC adenocarcinoma, AS adenosquamous carcinoma, LAVRT laparoscopic-assisted vaginal
radical trachelectomy, ART abdominal radical trachelectomy, VRT vaginal radical trachelectomy, RRT robotic radical trachelectomy
aOnly mean follow up is reported
#Crude recurrence and mortality rates among those who successfully had fertility preservation

















risk of increased surgical morbidity without the benefit
of improved oncologic outcomes. A review by Reade et
al. identified 341 patients who had undergone simple
hysterectomy or simple trachelectomy for the treatment
of stage ≥ IA2 cervical cancer. They found a crude recur-
rence rate of 6.3 %, and a crude disease-related mortality
rate of 1.5 % [11], which are comparable to those
achieved by radical trachelectomy [49, 51]. Given these
findings, non-radical surgery (simple trachelectomy or
conization) could be considered for fertility-sparing in
the management of small lesions with favourable prog-
nostic features [55, 56, 60].
Our review of the literature identified 203 cases of
early-stage cervical cancer eligible for non-radical,
fertility-sparing surgery (Table 6). All patients had
lesions <2 cm. Sixty patients underwent simple trache-
lectomy, and 138 underwent conization. Among 185
cases where fertility-sparing was successful, the crude
recurrence rate was 2.7 % and the crude mortality rate
was 0.5 %. Among 124 women where fertility preserva-
tion was successful, we identified 71 pregnancies with a
live birth rate of 68 % (Table 7). Both oncologic
outcomes and pregnancy rates compare favourably to
literature reports of those undergoing radical trachelec-
tomy. However, it should be noted that the available data
is from non-randomized studies of highly selected
patient populations with more favourable prognostic
factors compared to those undergoing radical surgery.
We identified three ongoing prospective trials de-
signed to assess the efficacy of non-radical surgery in the
treatment of low-risk early-stage cervical cancer. The
SHAPE trial (NCT01658930) is a randomized trial
comparing simple hysterectomy to radical hysterectomy
(or cone biopsy to radical trachelectomy) in addition to
pelvic lymph node assessment for cases of early-stage
Table 2 Histopathologic features among recurrences after radical
trachelectomy (N = 56)
























No intermediate/high risk features 19










Bernardini 2003 [114] 80 39 22 4 18 –
Hertel 2006 [29] 106 – 18 3 12 (3) 29 (1–128)
Shepherd 2006 [108] 112 63 55 – 28 (3) 45a (1–120)
Li 2011 [53] 56 10 2 0 1 (1) 23 (1–78)
Plante 2011 [57] 110 – 106 29 77 95 (4–225)
Kim 2012 [115] 77 35 27 7 20 –
Wethington 2012 [110] 70 38 31 9 16 (6) 32 (1–124)
Cao 2013 [51] 150 77 20 9 14 25 (6–91)
Nishio 2013 [116] 114 69 31 5 21 (5) 33
Vieira 2015 [113] 83 34 19 5 10 (4) 51 (10–147)
Hauerberg 2015 [112] 108 72 77 21 53 (3) 55.7 (5.5–147)
Kasuga 2016 [117] 172 109 61 13 43 (5) –
Total 1238 546 469 105 313 (30)
Crude rates
(%)
TI/T2 loss rate = 22.4 % Live birth rate = 66.7 % &
Abbreviations: T1 first trimester, T2 second trimester
aOnly mean follow up is reported
#Excludes those who had completion hysterectomy, or received fertility-compromising adjuvant treatment
& Does not include ongoing pregnancies
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(IA2–IB1 < 2 cm), low-risk (stromal invasion <10 mm on
LEEP/cone, or <50 % on MRI) cervical cancer [61]. The
goal is to demonstrate that in selected cases, non-radical
surgery (simple hysterectomy or cone biopsy) is non-in-
ferior to the gold standard radical surgery (radical hys-
terectomy or radical trachelectomy) with respect to
oncologic safety. Treatment-related morbidity, quality of
life, and cost-effectiveness are also being evaluated.
ConCerv (NCT01048853) is a prospective, international,
multicenter cohort study. The goal is to assess the
oncologic safety and feasibility of simple hysterectomy
or cone biopsy for early-stage (IA2–IB1 < 2 cm) low-risk
(negative LVSI, negative margins on cone specimen)
cervical cancer [62]. GOG 278 (NCT01649089) is a large
prospective cohort study [63]. This study’s primary
objectives are to examine the changes before and after
non-radical surgical treatment (simple hysterectomy or
cone biopsy for fertility preservation plus pelvic lymph-
adenectomy) on functional outcomes of bladder, bowel
and sexual function for early stage cervical cancer.
Women with stage IA1 (LVSI+) and IB1 (<2 cm)
carcinoma of the cervix with ≤ 10 mm of invasion on
diagnostic pathology are eligible for entry. After a pre-
operative survey on quality of life, women are stratified
based on desire to preserve fertility. Those desiring
fertility preservation undergo conization, whereas those
not desiring future fertility undergo extrafascial hyster-
ectomy. All patients undergo pelvic lymphadenectomy.
Patients with high-risk features on final pathology are
offered appropriate adjuvant treatment, and are
followed for survival only. Otherwise, patients undergo-
ing non-radical (simple hysterectomy) and fertility-
sparing (conization) surgery are assessed at routine
post-operative visit and every 6 months there-after for
validated quality of life measures, including surgical
morbidity, sexual function, fertility intentions, repro-
ductive concerns and impact of therapeutic choice
overall. Efficacy (recurrence) is an important secondary
objective.
It is hoped that these trials will help to define a select
group of patients for whom non-radical surgical man-
agement is oncologically safe.
Table 4 Oncologic outcomes of radical trachelectomy for lesions ≥ 2 cm (where N > 10 reported)
Study N with lesions≥ 2 cm
who underwent fertility
sparing surgery





Marchiole 2007 [109] 21 LAVRT 6 (7, 11, 18, 20, 21, 93) 4 (21, 24, 27, 41) 95 (31–234)
Nishio 2009 [118] 13 ART 5 (4, 8, 14, 18, 23) 0 27 (1–67)
Cao 2013 [51] 48 VRT
ART
5 (−) 2 (−) 34.3a
Li 2013 [119] 61 ART 0 0 30 (2–108)
Lintner 2013 [120] 31 ART 4 (5, 6, 10, 14) 2 (16, 22) 90 (60–148)
Wethington 2013 [121] 15 ART
LAVRT
VRT
1 (9) 0 44 (1–90)
Total N = 189 N = 21 N = 8
Crude rates (%) Recurrence rate = 11.1 %# Mortality rate = 4.2 %#
Abbreviations: LAVRT laparoscopic-assisted vaginal radical trachelectomy, ART abdominal radical trachelectomy, VRT vaginal radical trachelectomy
aOnly mean follow up is reported
#Crude recurrence and mortality rates among those who successfully underwent fertility sparing surgery, notwithstanding adjuvant treatment received










Cao 2013 [51] 48 24 3 0 3 34.3a
Li 2013 [119] 55 9 3 2 1 30.2 (2–108)
Lintner 2013 [120] 31 8 4 1 3 90 (60–148)
Total 134 41 10 3 7
Crude rates
(%)
T1/T2 loss rate = 30 % Live birth rate = 70 %
Abbreviations: T1 first trimester, T2 second trimester
aOnly mean follow up is reported
#Excludes those who had completion hysterectomy, or received fertility-compromising adjuvant treatment
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Bulky (2–4 cm) early-stage disease and the use of neoad-
juvant chemotherapy
For 2–4 cm FIGO stage IB1 and IIA disease, neoadju-
vant chemotherapy (NACT) has been shown to reduce
nodal metastases, parametrial infiltration, and overall
tumour size, theoretically making otherwise unresectable
(for fertility preserving purposes) disease amenable to
surgical management [64–66]. Although meta-analysis
of the available data has yet to show a survival advantage
for the use of NACT in early cervical cancer, its use in
the context of fertility preservation has been gaining
attention [66].
Our literature review identified 80 cases of ≥2 cm
stage IB1–IIA disease eligible for NACT prior to
fertility-sparing surgery (Table 8). The crude recurrence
rate is 6.3 % and one patient died from her recurrent
disease. The use of NACT has resulted in at least 36
pregnancies with a 72.2 % live birth rate (Table 9).
The timing of nodal assessment with respect to NACT is
not standardized. A study by Vercillino et al. in 2012
Table 6 Oncologic outcomes of non-radical fertility sparing procedures (where N > 10 reported)












Bisseling 2007 [122] 18 18 cone 18 0 0 72a
Rob 2007 [123] 26 15 ST
7 cone
20 1 (14) 0 49 (18–84)
Landoni 2007 [124] 11 11 cone 11 0 0 20 (7–29)
Fagotti 2011 [125] 17 17 cone 13 0 0 16 (8–101)
Maneo 2011 [126] 36 36 cone 31 3 (20, 34, 36) 1 (72) 66 (18–168)
Raju 2012 [127] 15 15 ST 15 0 0 96 (12–120)
Palaia 2012 [128] 14 14 ST 14 0 0 38 (18–96)
Plante 2013 [129] 16 16 ST 16 0 0 27 (1–65)
Andikyan 2014 [130] 10 9 cone
1 cx bx
9 0 0 17 (1–83)
Bouchard-Fortier 2014 [55] 29 29 cone 29 0 0 21 (1–112)
Salihi 2015 [131] 11 11 cone 9 1 (40) 0 58 (13–122)
Total 203 138 Cone
60 ST
185 N = 5 N = 1
Crude rates (%) Recurrence rate = 2.7 %# Mortality rate = 0.5 %#
Abbreviations: ST simple trachelectomy, cx bx cervical biopsy
aOnly mean follow up is reported
#Crude recurrence and mortality rates among those who successfully underwent fertility sparing surgery, notwithstanding adjuvant treatment received
Table 7 Obstetrical outcomes of non-radical fertility sparing procedures (where N > 10 reported)
Study Successful fertility
sparing management#





Bisseling 2007 [122] 18 18 5 13 72a
Rob 2007 [123] 20 15 6 8 (1) 49 (18–84)
Landoni 2007 [124] 11 3 0 3 20 (7–29)
Fagotti 2011 [125] 13 2 0 2 16 (8–101)
Maneo 2011 [126] 31 21 6 14 (1) 66 (18–168)
Raju 2012 [127] 15 4 0 4 96 (12–120)
Plante 2013 [129] 16 8 0 4 (4) 27 (1–65)
Total 124 71 17 48 (6)
Crude rates
(%)
T1/T2 loss rate = 23.9 % Live birth rate = 67.6 % &
Abbreviations: T1 first trimester, T2 second trimester
aOnly mean follow up is reported
#Excludes those who had completion hysterectomy, or received fertility-compromising adjuvant treatment
& Does not include ongoing pregnancies
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showed higher rates of recurrence among a subset of
women with positive nodes, in whom fertility-sparing sur-
gery was aborted, compared to women with negative nodes
that went on to have NACT and VRT. They suggested that
nodal assessment prior to NACT identifies a high-risk
group in whom fertility preservation should be avoided
[43]. Conversely, some contend that the use of NACT prior
to lymph node assessment in these patients may result in
fewer nodal metastases, and thus a higher number of pa-
tients eligible for fertility-sparing surgery [43]. Our review
of the literature identified only 3 series where nodal assess-
ment was carried out prior to NACT (Table 6). While
nodal involvement is one of the most significant negative
prognostic factors in early-stage cervical cancer, up-front
lymph node assessment could theoretically be used to tailor
NACT regimen, rather than to exclude potential candidates
for fertility-sparing surgery [43].
Advanced-stage disease
For patients who require hysterectomy and/or pelvic
radiotherapy, fertility preservation depends on assisted
reproductive technologies. Recognized options include
oocyte or embryo cryopreservation prior to cancer
therapy and ovarian transposition [5, 67]. The American
Society for Reproductive Medicine in 2013 argues that
given similar fertilization and pregnancy rates to IVF/
ICSI with fresh oocytes, oocyte cryopreservation should
no longer be considered experimental [68]. Fertility
preservation options that are still considered investiga-
tions include ovarian tissue cryopreservation/transplant-
ation and uterine transplantation [5, 69, 70].
The estimated lethal radiation dose to destroy 50 % of
oocytes is ≤2 Gy [71] and dependent on age, doses as
low as 6 Gy can render a woman menopausal, [72, 73].
The uterus also undergoes irreversible damage after

















Maneo 2008 [65] 21 After NACT (2) TIP/TEP x 3 Cone 0a 0 69 (10–124)
Robova 2010 [132] 15 After NACT (1) TI/TAx3 ST 3 (−) 1 (−) 76.5 (17–142)
Marchiole 2011 [64] 7 After NACT (0) TIP/TEP x2-3 VRT 0 0 22 (5–49)
Vercecllino 2012
[133]
6 Before NACT (0) 1-TP
5-TIP
VRT 0 0 30.6 (8–70)
Lanowska 2014
[134]
20 Before NACT (0) TIP/TP × 2-3 VRT 1 (20) 0 23 (1–88)
Salihi 2015 [131] 11 Before NACT (1) 2 TIP x3
4 ddCP x3
5 wCP x3
Cone 1 (40) 0 58 (13–122)
Total N = 80 N = 5 N = 1
Crude rates (%) Recurrence rate = 6.3 %# Mortality rate = 1.3 %#
Abbreviations: NACT neoadjuvant chemotherapy, LN lymph node, ST simple trachelectomy, VRT vaginal radical trachelectomy, TP cisplatin + paclitaxel, TI cisplatin +
ifosfamide, TA cisplatin + doxorubicin (for adenocarcinoma), TIP cisplatin + paclitaxel + ifosfamide, TEP cisplatin + paclitaxel + epirubicin (for adenocarcinoma), ddCP
dose dense carboplatin + paclitaxel, wCP weekly carboplatin + paclitaxel
#Crude recurrence and mortality rates among those who successfully underwent fertility sparing surgery, notwithstanding adjuvant treatment received
aN = 3 patients developed CIN in the residual cervix
Table 9 Obstetrical outcomes of fertility-sparing surgery after NACT (where N > 5 reported)
Study Successful fertility
sparing management#





Maneo 2008 [65] 16 10 1 9 69 (10–124)
Robova 2010 [132] 12 7 0 6 (1) 76.5 (17–142)
Marchiole 2011 [64] 7 1 0 0 (1) 22 (5–49)
Lanowska 2014 [134] 18 7 2 4 (1) 23 (1–88)
Salihi 2015 [131] 9 11 4 7 58 (13–122)
Total 62 36 7 26 (3)
Crude rates (%) 19.4 % T1/T2 loss rate 72.2 % live birth rate
Abbreviations: T1 first trimester, T2 second trimester
#Excludes those who had completion hysterectomy, or received fertility-compromising adjuvant treatment
& Does not include ongoing pregnancies
Willows et al. Gynecologic Oncology Research and Practice  (2016) 3:9 Page 9 of 14
doses from 14 to 30 Gy via reduced uterine volume,
reduced elasticity of the uterine musculature and uterine
vascular damage [71, 74].
Ovarian transposition was developed as a method to
protect the ovaries from the effects of radiation. Due to
the theoretical risk of remigration of the ovaries, the
ASCO recommendations on fertility preservation
suggest performing the transposition as close to the
radiation treatment date as possible [5]. Even after the
ovaries are transposed, short-term hormonal function is
preserved in only approximately 50–93 %, with failure
likely related to radiation scatter, remigration, and com-
promised ovarian blood supply [5, 75–80]. For all of the
above reasons, we feel it is important that Gynecologic
Oncologists familiar with the radiation borders perform
such surgeries. Hwang et. al demonstrated that transpos-
ing the ovaries more than 1.5 cm above the iliac crest
was significantly associated with successful preservation
of ovarian function after treatment [81]. Despite
increased success with higher fixation, the Royal College
of Obstetricians and Gynecologists recommends that
oocyte retrieval be considered for cervical cancer
patients prior to the administration of radiation therapy
due to the significant risk of ovarian failure after
transposition [82]. New random-start ovarian hyperstim-
ulation protocols decrease total time for the IVF cycle
without compromising oocyte yield and maturity [83].
Apart from the risk of failure of ovarian transposition,
there is also a concern about the risk of metastases in
transposed ovaries [84–86]. Given that oophorectomy is
not part of the standard treatment of cervical cancer,
this risk is not considered prohibitive. Regardless, it
seems that ovarian transposition is provided to only a
small fraction of eligible patients [87]. A study Salih et.
al. in 2015 also suggested that few cervical cancer
patients who undergo ovarian transposition end up
pursuing in vitro fertilization [88]. The reality is that
patients who undergo ovarian transposition require a
gestational carrier, which is fraught with ethical, financial
and legal issues [89]. Although successful pregnancies
have been reported for cervical cancer patients after
oocyte retrieval from transposed ovaries and transfer to
a gestational carrier, these reports are rare [90–92]. It
seems that for most women, the main benefit of ovarian
transposition is maintenance of hormonal function
rather than preservation of fertility.
Experimental technique for fertility preservation
Ovarian tissue cryopreservation is an experimental tech-
nique for fertility preservation. It is sometimes offered to
patients who require immediate gonadotoxic treatment
of malignancies where there is insufficient time to offer
ovulation induction and cryopreservation of oocytes or
embryos. Ovarian tissue can be cryopreserved as cortical
biopsies, cortical strips or as whole ovaries, but only
cortical biopsies and strips have been successfully trans-
planted after cryopreservation [69]. The ovarian tissue
can be transplanted into a pelvic (orthotopic) or extra-
pelvic (heterotopic) site. When cortical strips are trans-
planted orthotopically, they are transplanted either into
the medulary portion of a remaining ovary or onto the
peritoneum of the ovarian fossa [69]. Studies have re-
ported normal menstrual cycles within 4–9 months after
transplantation and graft survival from several months
up to 7 years [69, 93–96]. There have been at least 24
births reported after orthotopic transplantation of cortical
ovarian tissue, but many of these reports are confounded
by the presence of native ovarian tissue [69, 95, 97–99].
Locations of heterotopic transplantation of ovarian tissue
resulting in restoration of ovarian function include the
forearm, abdominal wall and chest wall [69, 100–102].
Although oocyte retrieval and fertilization with IVF have
been reported, there have been no reported live births
with this technique. The risk of malignancy from auto-
transplanted ovarian tissue in cancer patients is not clear,
but in a systematic review of 289 patients, metastases were
common in patients with leukemia, but less common in
most other cancers including cervical cancer [103].
Another experimental procedure that has had recent
media attention is uterine transplantation. A 1-year
follow-up report of the first uterine transplant trial was
published in 2015 [104]. The trial involved uterine trans-
plantation in 9 patients with normal ovarian function
who had previously undergone IVF and had cryopre-
served embryos. One patient had a history of hysterec-
tomy for cervical cancer. Of the 9 transplanted uteri, 2
were removed within the first 6 months, one due to
chronic infection and the other due to bilateral uterine
vessel thrombosis. In addition to these grade III surgical
complications in the recipients, one of the donors
developed a ureterovaginal fistula. Participants were
placed on an immunosuppressive protocol. After 1 year
of follow-up, 5 of the 7 recipients who kept their trans-
planted uterus experienced rejection episodes which
were all asymptomatic and managed with an intensifica-
tion of the immunosuppressive regimen. Spontaneous
menses occurred in all 7 women within 2 months of
transplantation. The plan was to transfer embryos after
12–18 months post-transplant, and a 4–6 month
rejection-free period, and to remove the uterus after 1–2
successful pregnancies. As of December, 2015 there were
apparently 4 healthy babies born to this cohort [70].
Patient reported outcomes after fertility-sparing
management
While we have made impressive technological advances
in early cervical cancer management, the long-term
effects of cancer survivorship on quality of life are still
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not fully understood [105]. Several prospective observa-
tional studies have assessed patient reported outcomes
after fertility-sparing surgery in early cervical cancer. In
2010, Carter et al. conducted a 2-year prospective study
assessing the emotional, sexual, and quality of life
concerns of women undergoing radical trachelectomy
versus radical hysterectomy for treatment of early-stage
cervical cancer [105]. Pre-operatively, both groups
reported increased depression, distress, and sexual
dysfunction. Although these measurements improved
over time, they did not differ significantly by surgery
type. This highlights the challenges faced by young
cancer survivors in general. After a few years of proced-
ural experience with non-radical fertility-sparing surgery,
Song et al., in 2013, examined the effects of surgical
radicality on sexual functioning [106]. Women who had
undergone non-radical surgery experienced less sexual
dysfunction than those who had undergone radical
surgery. There was no difference between those who had
undergone radical trachelectomy versus radical hysterec-
tomy [106]. While these non-randomized studies gener-
ate important hypotheses, they are limited by small
sample sizes.
In addition to GOG 278, a prospective questionnaire-
based study is currently assessing quality of life and
sexual function in women who have undergone radical
abdominal trachelectomy [107]. It is expected that these
studies will shed light on the patient experience, both in
terms of fertility-sparing and non-radical management
of early-stage cervical cancer.
Conclusions
Today, many cervical cancer survivors have the option
of becoming a parent. For those with early-stage disease,
minimally invasive and fertility sparing techniques have
resulted in improved obstetrical outcomes without
compromising oncologic safety. For others, natural
fertility and childbearing may be unachievable. However,
advances in assisted reproductive technologies continue
to make pregnancy and/or parenthood a possibility for
those who desire it.
Several questions still remain. The safety of non-radical,
fertility-sparing surgery has mainly been demonstrated in
the context of small, non-randomized comparisons that are
fraught with selection bias. The appropriate timing of
NACT with respect to nodal assessment, in this context,
has yet to be elucidated. The significance of nodal
micrometastases remains unclear. For those fortunate
enough to undergo fertility preservation and achieve
pregnancy, management should be standardized. Centres of
excellence should be established, involving gynecologic
oncologists, reproductive endocrinologists, maternal fetal
medicine specialists, and psychologists specializing in
sexual and reproductive health. Ultimately, as we continue
to seek answers to our objective questions, the patient-
centered purpose of this quest should not be forgotten.
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